Skip to main content
Jasgit (Chugh) Sachdev, MD, Oncology, Tempe, AZ

Jasgit C (Chugh) Sachdev MD

Oncology•Tempe, AZ

Director, Breast and GYN Early Trials

Join to view full profile

  • 1931 E Brentrup DrTempe, AZ 85283

  • Phone+1 901-605-6652

  • Fax+1 901-722-0466

Dr. Sachdev is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Sachdev's full profileAlready have an account?

Education & Training

  • University of Tennessee College of Medicine
    University of Tennessee College of MedicineFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Creighton University School of Medicine (Omaha)
    Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 2001 - 2004
  • Dayanand Medical College
    Dayanand Medical College Class of 2000

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2010 - 2027
  • MS State Medical License
    MS State Medical License 2007 - 2012
  • TN State Medical License
    TN State Medical License 2007 - 2012
  • AR State Medical License
    AR State Medical License 2008 - 2010

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2014
  • CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

  • Five Prime Therapeutics Presents Monotherapy Data from the Phase 1a/1b Trial of FPA150 in Patients with Advanced Solid Tumors at the 2019 ASCO Annual Meeting
    Five Prime Therapeutics Presents Monotherapy Data from the Phase 1a/1b Trial of FPA150 in Patients with Advanced Solid Tumors at the 2019 ASCO Annual MeetingJune 1st, 2019
  • Dr. Jasgit Sachdev on What's on the Horizon for Ovarian Cancer
    Dr. Jasgit Sachdev on What's on the Horizon for Ovarian CancerNovember 23rd, 2016
  • Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer
    Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian CancerOctober 25th, 2016

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Jasgit Sachdev, Dr. Jasgit Sachdev, MD, Dr. J Sachdev, Dr. Jasgit C Sachdev